Establishing a core dossier for multiple regulatory submissions: a case study in the Latin America region
Frontiers in Medicine · 16.05.2023 · 10
DOI: 10.3389/fmed.2023.1102452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 16.05.2023. Verfasst von Alva Lucia Alvarez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Regulatory Affairs International, Pfizer Ltd, Bogotá, Colombia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Latin America region comprises several countries that do not follow harmonized regulatory requirements for drug product (DP) marketing authorization applications (MAA), resulting in customized registration dossiers for each country. Here, we established a core dossier for multiple MAA in the Latin America region by examining the similarities between regulatory requirements and reconciling their potential discrepancies through discussions among all national regulatory representatives. The core dossier was used in the submission of a new small molecule, NME1, to nine markets. Assessment of the process included the time to submission; the timing, number, and complexity of questions received; and timing of final national regulatory agencies (NRA) evaluation decisions. The core dossier resulted in an accelerated submission timeline for most markets and earlier receipt of NRA queries from some markets, compared with projections. One round of queries of a low or medium complexity was received from all agencies. The receipt of final NRA evaluation decisions was also accelerated in most markets, compared with the best-case approval timeframes. The core dossier approach was also evaluated against the standard submission of a similar small molecule, NME2. In contrast to the core dossier submission of NME1, a second round of questions, and high-complexity questions were received from two markets for NME2. In conclusion, a core dossier has the potential to simplify the regulatory process for both reviewers and applicants in regions that do not share harmonized regulatory requirements, with a consequential acceleration of DP approvals.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Regulatory Affairs International, Pfizer Ltd, Bogotá, Colombia.
- Global Regulatory Affairs International, Pfizer Ltd, San Juan, PR, United States.
- Global Regulatory Affairs International, Pfizer Ltd, New York, NY, United States.
- Global Regulatory Policy and Intelligence, Global Regulatory Affairs, Pfizer Ltd, Tadworth, Surrey, United Kingdom.
- Global Regulatory Affairs Operations, Pfizer Ltd, São Paulo, Brazil.
Zitieren
APA
Alvarez, A. L., Maisonet, I. O., Ruiz, O., Lumsden, R. S., Ferreira, A. P. E., & Avila Flores, E. M. (2023). Establishing a core dossier for multiple regulatory submissions: a case study in the Latin America region. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1102452
Vancouver
Alvarez AL, Maisonet IO, Ruiz O, Lumsden RS, Ferreira APE, Avila Flores EM. Establishing a core dossier for multiple regulatory submissions: a case study in the Latin America region. Frontiers in Medicine. 2023;10. doi:10.3389/fmed.2023.1102452
BibTeX
@article{Alvarez2023,
author = {Alvarez, Alva Lucia and Maisonet, Irma O and Ruiz, Omar and Lumsden, Rebecca S and Ferreira, Ana Paula Evangelista and Avila Flores, Esther M},
title = {Establishing a core dossier for multiple regulatory submissions: a case study in the Latin America region},
journal = {Frontiers in Medicine},
year = {2023},
volume = {10},
doi = {10.3389/fmed.2023.1102452}
}
EUVIMED